Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma.

Clinical and experimental medicine - 17 Jan 2026

Sun Yi, Cheng Qiang, Zhou Qiaoxia, Xu Yu, Wang Guoqiang, Xu Chunwei, Wang Wenxian, Cai Shangli, Chen Wenzheng

Abstract excerpt

Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced clear cell renal cell carcinoma (ccRCC), but the biomarkers predicting benefits from ICI-based therapies over conventional VEGFR/mTOR inhibitors remain incompletely elucidated. In this study, we analyzed clinical, mutational, and/or transcriptomic data of multiple cohorts, including five clinical trials (JAVELIN Renal 101...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Immune Checkpoint Inhibitors

Share to Kidney Neoplasms

Share to Neurofibromin 2

Share to Receptors, Vascular Endothelial Growth Factor

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 41546842
DOI: 10.1007/s10238-025-01885-8
PMCID: PMC12847219

Genes

NF1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma.PMID 41546842Read ↗

Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the LiteratureSemantic proximity Read ↗

Multi-omics features-based machine learning method improve immunotherapy response in clear cell renal cell carcinomaSemantic proximity Read ↗

Identification and Comprehensive Validation of a DNA Methylation-Driven Gene-Based Prognostic Model for Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma.Semantic proximity Read ↗

Exploring the crosstalk between the FGF/FGFR pathway and tumor microenvironment in clear cell renal cell carcinomaSemantic proximity Read ↗

Integrative Bioinformatics Analysis Reveals New Prognostic Biomarkers of Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2.Semantic proximity Read ↗

APOBEC family reshapes the immune microenvironment and therapy sensitivity in clear cell renal cell carcinoma.Semantic proximity Read ↗

Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.Semantic proximity Read ↗

Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.Semantic proximity Read ↗

Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profilesSemantic proximity Read ↗

[Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.